Cancer

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costsTogether with GSK, ended Pandemic…

9 months ago

CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Mr. Ramanayake brings more than fifteen years of experience in biopharma company development and deal-makingStrong track record of successful clinical…

9 months ago

CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK

Phase 1 part of combined Phase 1/2 study initiated as part of pandemic preparedness against highly pathogenic avian influenza (H5N1)…

9 months ago

Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement

TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF)(FRA:TTX), a clinical stage…

9 months ago

Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad

LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today data from…

9 months ago

Angle PLC Announces New Commercial Agreement with AstraZeneca

ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D GUILDFORD, SURREY / ACCESSWIRE…

9 months ago

Anne Arundel Dermatology Adds Intelligent Scheduling Capabilities to Improve Patient Experience

Relatient’s centralized scheduling platform and patient self-scheduling tools will enhance patient access while streamlining staff workflowsATLANTA--(BUSINESS WIRE)--#DashEngage--Anne Arundel Dermatology (AADerm),…

9 months ago

CNS Pharmaceuticals to Present at the LSX World Congress 2024

Presentation on Monday, April 29th at 4:15 PM (GMT+1)HOUSTON, TX / ACCESSWIRE / April 23, 2024 / CNS Pharmaceuticals, Inc.…

9 months ago

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Provides Further Evidence of Multiple Opportunities for Development of the FABP Inhibitor Platform in Cancer & Other Serious ConditionsSOLANA BEACH,…

9 months ago